Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Mylan's COVID-19 Medicine, And Other News: The Good, Bad And Ugly Of Biopharma
11:20am, Sunday, 22'nd Mar 2020
Mylan resurrected an old medicine for COVID-19 treatment. Lexicon shuts Zynquista study. Celsion reports positive cancer data.
The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus
12:00am, Sunday, 22'nd Mar 2020
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Biotech stocks went on a roller...
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
12:30pm, Thursday, 19'th Mar 2020
Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 --.
R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to.
Celsion CEO Issues Letter to Stockholders
01:30pm, Tuesday, 03'rd Mar 2020
Celsion Corporation (CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following lette
W, VMW among premarket losers
02:17pm, Friday, 28'th Feb 2020
Big Lots (NYSE:BIG) -35% on Q4 earnings.Tonix Pharmaceuticals (NASDAQ:TNXP) -23% after pricing stock offering.Celsion (NASDAQ:CLSN) -19% after pricing registered direct offering.Wayfair (NY
Celsion Corporation Prices $4.8 Million Registered Direct Offering
01:45pm, Friday, 28'th Feb 2020
The Company has also agreed to issue to such investors, in a concurrent private placement, warrants to purchase 2,971,428 shares of the Company’s common stock. The gross proceeds of the offering wi
When Can We Expect A Profit From Celsion Corporation (NASDAQ:CLSN)?
11:20am, Tuesday, 25'th Feb 2020
Celsion Corporation's (NASDAQ:CLSN): Celsion Corporation, a development stage oncology drug company, focuses on the...
Ziopharm Secondary, And Other News: The Good, Bad And Ugly Of Biopharma
11:10pm, Monday, 10'th Feb 2020
Ziopharm announced a dilutive secondary share offering. Gilead's earnings call and new strategy. Celsion has new safety data.
Celsion Corporation (CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its initial safety review of data from the first fifteen patients treated with the fi
Celsion Corporation (CLSN), an oncology drug-development company, announces that Prof. Riccardo Lencioni, M.D., FSIR, EBIR delivered a presentation titled “Thermally-Sensitive Ablation Enhancers: Wh
